|
|
Post by myocata on Sept 3, 2015 14:22:29 GMT
My first batch was in summer 08 and I haven't sold a single share since then. Maybe I'll will this time..... 7 years itch.
|
|
|
|
Post by thechurchmaus on Sept 3, 2015 16:09:25 GMT
i dont think any of those trades are for real today.just computers talking to each other.trying to take advantage of a slow market with people taking an early holyday weekend.they are doomed but pride gets them further in the hole.young turks playing with BPs money.
|
|
|
|
Post by JHam on Sept 3, 2015 16:12:04 GMT
i dont think any of those trades are for real today.just computers talking to each other.trying to take advantage of a slow market with people taking an early holyday weekend.they are doomed but pride gets them further in the hole.young turks playing with BPs money. What are you talking about? Of course they are real. Over 350K shares traded and I am sure that at least some of them were done by real human beings  |
|
|
|
Post by jckrdu on Sept 3, 2015 16:14:19 GMT
Added at $4.52.
Will wait to add more until I see a bottom formed.
|
|
|
|
Post by jckrdu on Sept 3, 2015 16:26:35 GMT
Added at $4.52. Will wait to add more until I see a bottom formed. Added more at $4.57 after seeing it bounce off $4.50. I see a little support in the chart at $4.50 (look at 5 day and 3 month charts). |
|
|
|
Post by jckrdu on Sept 3, 2015 16:30:09 GMT
Added at $4.52. Will wait to add more until I see a bottom formed. Added more at $4.57 after seeing it bounce off $4.50. I see a little support in the chart at $4.50 (look at 5 day and 3 month charts). Too early to say if $4.50 is the near-term bottom IMO, but I'm hoping it is and we trend back up from here on expectations of Lupus data and other September news.
I'm fully loaded with OCAT, and don't intend to add more unless that gap between $4.23 and $4.26 fills.
GL.
|
|
|
|
Post by jckrdu on Sept 3, 2015 16:52:36 GMT
Added more at $4.57 after seeing it bounce off $4.50. I see a little support in the chart at $4.50 (look at 5 day and 3 month charts). Too early to say if $4.50 is the near-term bottom IMO, but I'm hoping it is and we trend back up from here on expectations of Lupus data and other September news.
I'm fully loaded with OCAT, and don't intend to add more unless that gap between $4.23 and $4.26 fills.
GL.
Higher probability that $4.50 was the bottom as we've recovered back over $4.60.
Looking for a strong rest of the day. We'll see.
GL all.
|
|
|
|
Post by myocata on Sept 3, 2015 17:13:16 GMT
Am done buying in the 3. Am just waiting the right PPS to dump my loads.....
|
|
|
|
Post by selluwud on Sept 4, 2015 14:09:48 GMT
Could be heading for the 4.23-4.26 gap. Not to worry, upward from there with new bottoms forming as we go.
|
|
|
|
Post by selluwud on Sept 4, 2015 19:15:12 GMT
Price held up pretty well considering the pounding the DJI is taking today.
|
|
|
|
Post by RLC on Sept 8, 2015 13:02:55 GMT
|
|
|
|
Post by thechurchmaus on Sept 8, 2015 13:37:09 GMT
are they going to get it down the usual 5% just to rub it in?when you can make yourself unlimited shares it should be childs play.
|
|
|
|
Post by thechurchmaus on Sept 8, 2015 16:07:56 GMT
the consortium of hedgefunds controlling trillions of dollars are walking us down into the red again step by step playing their shorting game with emerging biotechs.
|
|
|
|
Post by thechurchmaus on Sept 8, 2015 16:48:45 GMT
funny... somebody bought their blockers before they could withdraw them as usual.110000 share buy.
|
|
|
|
Post by selluwud on Sept 9, 2015 14:43:15 GMT
Heading for the 4.47-4.51 gap from yesterday?
|
|
|
|
Post by jckrdu on Sept 9, 2015 15:53:50 GMT
Heading for the 4.47-4.51 gap from yesterday? Could be Sell. It may retrace and fill that gap if we don't see more news over the next several days.
3-month chart still looks good with general uptrend still intact and consolidation happening at $4.50ish. Need news (Lupus data, SPA, SMD start) to continue the uptrend.
|
|
|
|
Post by selluwud on Sept 9, 2015 17:04:52 GMT
Heading for the 4.47-4.51 gap from yesterday? Could be Sell. It may retrace and fill that gap if we don't see more news over the next several days.
3-month chart still looks good with general uptrend still intact and consolidation happening at $4.50ish. Need news (Lupus data, SPA, SMD start) to continue the uptrend.
Isn't there a live presentation today about HMC's treating autoimmune diseases (Lupus) by someone from Ocata? Kimbrel at 2:30 www.gtcbio.com/conferences/cell-gene-therapy-speakers |
|
|
|
Post by Wallace907 on Sept 9, 2015 17:26:53 GMT
Could be Sell. It may retrace and fill that gap if we don't see more news over the next several days.
3-month chart still looks good with general uptrend still intact and consolidation happening at $4.50ish. Need news (Lupus data, SPA, SMD start) to continue the uptrend.
Isn't there a live presentation today about HMC's treating autoimmune diseases (Lupus) by someone from Ocata? Kimbrel at 2:30 www.gtcbio.com/conferences/cell-gene-therapy-speakersI think john Lu is presenting soon as well, if he didn't already |
|
|
|
Post by CM kipper007 on Sept 9, 2015 17:30:09 GMT
Could be Sell. It may retrace and fill that gap if we don't see more news over the next several days.
3-month chart still looks good with general uptrend still intact and consolidation happening at $4.50ish. Need news (Lupus data, SPA, SMD start) to continue the uptrend.
Isn't there a live presentation today about HMC's treating autoimmune diseases (Lupus) by someone from Ocata? Kimbrel at 2:30 www.gtcbio.com/conferences/cell-gene-therapy-speakers2:20 Preclinical Development of a Pluripotent Stem Cell Based Therapy for Autoimmune Diseases Erin A. Kimbrel Director, Translational Research Ocata Therapeutics Pluripotent stem cells (PSCs) have important clinical potential in regenerative medicine given their ability to differentiate into any cell type in the body. While inefficient differentiation and concerns over potential tumorigenicity have hindered their clinical development, the first wave of PSC-based therapies is now being tested in clinical trials and showing safe application in humans. Additional PSC-derived products are being developed for treating a variety of diseases, including autoimmune disorders. Through a unique differentiation and manufacturing process, we have established a platform for the generation of highly potent immunomodulatory cells termed hemangio-mesenchymal cells, or HMCsTM from pluripotent stem cells. Preclinical data show strong therapeutic activity for HMCs in models of lupus nephritis, Crohn’s, multiple sclerosis, and autoimmune uveitis, principally through the secretion of paracrine-acting factors that alter the behavior of innate and adaptive immune cells. Starting from a pluripotent stem cell source, HMCs are both youthful and replenishable, representing the earliest stage of biological development. Preclinical evidence shows that these attributes afford HMCs greater potency than mesenchymal stromal cells, which are derived from primary tissue sources like bone marrow and umbilical cord. Moreover, banks of genotypically identical HMCs can be generated on a commercial scale without the need for extended in vitro culture or use of multiple donors, which facilitates a consistent final product. Various stages in the development of a pluripotent stem cell-based product like HMCs- from disease model testing to quality control in manufacturing to safety and biodistribution - will be addressed. Key points: 1. The current status of pluripotent stem cell (PSC)-based products in clinical trials 2. Preclinical evaluation of HMCs, a PSC-based product for treating autoimmune diseases 3. A comparison between the use of PSCs and primary tissues as sources for cell-based products 4. GMP lot release considerations and safety testing for PSC-based therapies |
|
|
|
Post by Wallace907 on Sept 9, 2015 18:23:03 GMT
|
|
